Anti-TNSF13B (Belimumab), Human IgG1 Antibody

Anti-TNSF13B (Belimumab), Human IgG1 Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a recombinant fully human IgG1 monoclonal antibody that specifically binds to soluble human B lymphocyte stimulator protein (BLyS), also known as B-cell activating factor (BAFF). BAFF belongs to the superfamily of Tumor Necrosis Factor (TNF) and plays a vital role in B-cell maturation and survival. It is produced by several cell types such as neutrophils, dendritic cells, and macrophages. Binding of BLyS to its receptors on the surface of B-cells activates downstream signaling pathways such as NF-κB and MAPK pathways that promote the expression of anti-apoptotic proteins and inhibit apoptosis. The antibody binds to BLyS, prevents the association with its receptors, and thereby reduces the survival of autoantibody-producing B-cells. The original drug received approval from the FDA to treat systemic lupus erythematosus.

Immunogen Sequence:Human TNFSF13B

Target Alternative Name:LymphoStat B, LymphoStat-B, DTL, BAFF, BLYS, CD257, TALL1, THANK, ZTNF4, TALL-1, TNLG7A, TNFSF20

Species Reactivities:Human

Tag Line:The biosimilar is a fully human recombinant monoclonal antibody that targets soluble human B lymphocyte stimulator protein (BLyS), prevents the binding with its receptor on B lymphocyte cell surface and inhibits B-cell mediated immune response

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:In vitro studies

Positive Control:/

Application And Usages:In vitro studies

Handling:The antibody solution should be gently mixed before use.